A June FDA advisory committee will be a huge moment for struggling bluebird bio. A positive decision by FDA coupled with the favorable ICER assessment could lead to a robust cash flow. Being considered cost-effective may offer Zynteglo a distinct advantage in its negotiations with payers.
Subscribe to:
Post Comments (Atom)
< + > Staffing, Outsourcing, and the Digital Workforce with Ray Lowe and HCTec
Staffing at health care providers, especially for IT, is being challenged on many fronts. Inflation is up while Medicaid has been significan...
-
The following is a guest article by Ladd Wiley, Senior Vice President for Global Corporate Affairs, Public Policy, and Advocacy at Epic , ...
-
Welcome to the weekly edition of Healthcare IT Today Bonus Features . This article will be a weekly roundup of interesting stories, product ...
-
Training artificial intelligence models on more diverse image and data sets can augment decision making, overcome knowledge gaps, and promot...
No comments:
Post a Comment